What was tested—Cosentyx added to inactivated vaccines?
I don’t have enough provided information to determine whether adding Cosentyx (secukinumab) to inactivated vaccines changed their efficacy. The answer depends on the specific study or dataset (which vaccine(s) were used, which patient population, and what endpoint was measured).
What counts as “efficacy” in these vaccine studies?
Vaccine “efficacy” in inactivated-vaccine–plus–Cosentyx settings is usually assessed by immunogenicity endpoints such as antibody titers or seroconversion rates after vaccination. Other studies may look at real-world protection or clinical outcomes, but those are much less common in controlled vaccine-immunogenicity research. Without the specific source, I can’t map “changed efficacy” to the correct endpoint.
How could Cosentyx affect inactivated vaccine responses?
If a study measures antibody responses after vaccination, immunosuppressive effects from blocking IL-17 (Cosentyx’s mechanism) could plausibly reduce or alter the magnitude/timing of antibody responses, even if the vaccine remains immunogenic. Whether that happens (and how much) is exactly what the trial results would show—and those results aren’t included in what you’ve provided.
What would be the key result to look for?
To answer your question precisely, you’d check whether the trial compared:
- inactivated vaccine alone vs.
- inactivated vaccine + Cosentyx (or continued Cosentyx during vaccination),
and then whether antibody responses (e.g., geometric mean titers, fold-rise, seroprotection/seroconversion) were statistically or clinically different.
If you share the study link, paper title, or the specific vaccine trial details (vaccine name and patient group), I can tell you directly whether adding Cosentyx changed efficacy based on the reported outcomes.
Sources
No sources were provided in the prompt, so I can’t cite specific evidence.